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Purpose: Vascular endothelial growth factor (VEGF) is well known for its role in pathologic neovascularization, including
wet age-related macular degeneration. However, a growing body of evidence indicates that VEGF is also neuroprotective
of non-vascular cells in various animal models through reduction of oxidative stress. In light of the widespread use of
intraocular anti-VEGF therapies for age-related macular degeneration (AMD), we evaluated the impact of anti-VEGF
agents on the neuroprotective effect of VEGF on retinal ganglion cells.
Methods: Staurosporine differentiated retinal ganglion cells were treated with increasing doses of VEGF in the presence
of hydrogen peroxide. After optimization, an increasing concentration of bevacizumab was added to neutralize VEGF-
mediated protection. The degree of oxidative damage was measured at various time points using buthionine sulfoxime
(BSO), a glutathione reductase inhibitor. Cell viability was assessed using WST-1 and Crystal violet assays.
Results: VEGF (200 ng/ml) protected differentiated retinal ganglion cells (RGC)-5 against H202-mediated oxidative stress.
This effect was eliminated by co-treatment with bevacizumab (2.0 mg/ml), which by itself was not cytotoxic.
Conclusions: These results indicate an important role for VEGF in the maintenance of retinal ganglion cells.
Vascular endothelial growth factor (VEGF), a secreted
46  kDa  glycoprotein,  is  an  endothelial  cell-specific
angiogenic as well as a vasopermeable factor [1,2]. Although
initially thought to be endothelial-specific, VEGF plays a
major role during the development and maturation of neural
tissue, including the retina [3]. During development, VEGF is
expressed by astrocytes in the retinal ganglion cell layer, by
cells of inner nuclear layer, Müller cells, and retinal pigment
epithelial cells [4,5]. In the adult retina, VEGF is expressed in
the absence of active neovascularization and is implicated in
the maintenance and function of adult retina neuronal cells
[6].  VEGF-A,  an  isoform  of  VEGF,  reduces  apoptosis  in
retinal neurons after ischemic injury and delays degeneration
of retinal ganglion cells after axotomy [7]. Upregulation of
VEGF  occurs  in  many  ischemic  conditions  of  the  retina,
including  age-related  macular  degeneration  (AMD)  and
diabetic retinopathy [8,9]. Higher intraocular VEGF levels
lead  to  subretinal  and  vitreous  hemorrhage,  retinal
detachment, and often blindness [10].
Intravitreal  injections  of  anti-VEGF  agents  such  as
bevacizumab are widely used in the treatment of AMD to
reduce  the  angiogenesis  associated  with  choroidal
neovascularization  [11,12].  Hypothetically,  repeated
treatment with anti-VEGF agents should interfere with the
neuroprotective action of VEGF. Recently, Saint-Geniez et al.
[6] have shown in animal studies that small, interfering RNA
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(siRNA)-mediated gene silencing of VEGF led to a reduction
in the thickness of retinal cell layers. They concluded that
VEGF has a neuroprotective role in the survival of retinal
neurons. In this study, we tested this hypothesis in a cell
culture model by investigating the neuroprotective effect of
VEGF on differentiated rat retinal ganglion cell, RGC-5 after
oxidative stress, and whether treatment with bevacizumab can
abrogate this effect. We used the oxidative stress model to
replicate the in vivo conditions, which are implicated in the
pathogenesis of macular degeneration. Further, we found that
retinal ischemic and oxidative injury leads to increased levels
of VEGF, resulting in angiogenesis.
METHODS
Cell culture: Rat retinal ganglion cells (RGC-5; Molecular
Brain Research 86 [2001]) [1–12] were supplied courtesy of
Dr. Neeraj Agarwal (UNT Health Science Center, Fort Worth,
TX) and were cultured in Dubelco’s Modified Eagle Medium
(DMEM: Invitrogen, Carlsbad, CA), containing 10% fetal
bovine  serum  (FBS)  and  100  U/ml  penicillin/100  μg/ml
streptomycin. All cells were maintained in logarithmic growth
in T-75 flaskware and incubated at 37 °C in a 95% air and 5%
CO2 environment.
Differentiation: RGC-5 cells were differentiated by treating
the  cells  with  Staurosporine  using  a  technique  previously
described [13]. Morphologic evidence of a neuron cell line
was determined using phase contrast bright-field microscopy.
Further,  immunocytochemistry  was  performed  using  a
monoclonal antibody against class III β-tubulin to confirm
differential expression of markers of neuronal differentiation.
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1848Oxidative  stress:  Different  concentrations  of  hydrogen
peroxide  (H2O2)  were  generated  using  serial  dilution  and
applied to the Staurosporine-differentiated RGCs for 24 h to
generate a dose response curve. Cell numbers were assessed
using  a  Water  Soluble  Tetrazolium  (WST)-1  (Roche,
Mannheim, Germany) assay. Briefly, WST-1 is a tetrazolium
salt that is cleaved by mitochondrial dehydrogenases in viable
cells, producing a proportionate color change. Plates were
then read on a spectrophotometer at 440 nm with reference
wavelength at 690 nm.
Subsequently,  differentiated  cells  were  treated  with
increasing  concentrations  of  human  VEGF  (hVEGF165;
Invitrogen) in adjacent wells with alternate wells containing
800 µM H2O2 for 24 h. The difference in cell number between
H2O2-treated and untreated wells were compared, using the
WST-1  assay  as  described  above.  The  aforementioned
experiment was repeated in the presence of 25 μM buthionine
sulfoxime (BSO), an inhibitor of glutathione (GSH) synthesis,
thereby enhancing oxidative stress in our model. Cells were
exposed to 25 μM BSO for 24 h following attachment and
differentiation. Increasing concentrations of hVEGF165 were
applied, followed by 24 h exposure to 800 μM H2O2.
To  evaluate  the  effect  of  bevacizumab  blockade  of
hVEGF165, we first conducted cytotoxicity experiments to
explore any potential effect in our differentiated model. Cells
were plated in 96-well plates at 2,000 cells/well, allowed to
attach  for  24  h,  and  subsequently  differentiated  with
Staurosporine.  Serial  dilutions  of  commercially  available
bevacizumab  (Avastin®:  Genentech,  San  Francisco,  CA)
were performed to obtain treatment concentrations of 0.1, 1.0,
and 2.0 mg/ml, and were applied for 24 h. H2O2 (1 mM) served
as  a  positive  control.  Cell  numbers  were  assessed  using
WST-1. Parallel experiments were conducted in a similar
fashion and evaluated with crystal violet staining (CV). In
brief, cells were fixed for 10 min in 4% formaldehyde, rinsed
twice  with  PBS  and  dried.  Cells  were  stained  with  0.1%
crystal violet solution for 30 min. Excess stain was washed
once with PBS and twice with distilled water. Plates were
Figure 1. Morphological and immunohistochemical differentiation of retinal ganglion cell (RGC)-5 cells. A: Phase contrast biomicroscopy
comparing undifferentiated with differentiated RGC-5 following exposure to Staurosporine. Note the elongated neuronal processes in the
treated cells. B: Antibody control for immunocytochemistry staining C: Immunocytochemistry staining for class III β-tubulin highlights the
elongated processes in Staurosporine treated cells. undiff: undifferentiated, diff: differentiated, AB: antibody control.
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10% acetic acid solution per well. Plates were read in a plate-
reader with a 560 nm filter.
In subsequent experiments, cells were plated in 96-well
plates  and  differentiated  as  described  above.  Increasing
concentrations  of  bevacizumab  were  added  to  wells
containing 200 ng VEGF165 and wells containing VEGF and
800 µM H2O2. Cell numbers using the WST-1 assay were
determined following 24 h exposure.
RESULTS
Differentiation:  Representative  bright-field  microscopy
images  demonstrate  morphologic  changes  between
differentiated and undifferentiated RGC-5 cells (Figure 1A).
Figure 2. Effects of vascular endothelial
growth  factor  (VEGF)  in  oxidative
stress  induced  cytotoxicity  in  retinal
ganglion  cell  (RGC)-5  cells.  A:
Hydrogen p 258 eroxide dose response
curve,  following  24  h  exposure,
revealed  30%–35%  reduction  in  cell
numbers  at  700  and  800  μM  doses.
Higher doses resulted in 80% reduction
(*p-value<0.005).  B:  VEGF-mediated
protection  was  evaluated  in  parallel
wells,  where  hydrogen  peroxide  (800
μM)-treated  cells  are  compared  with
cells treated with VEGF alone. There
was a reduction in percentage decrease
of  cell  numbers  when  cells  were  co-
treated with VEGF and H2O2, compared
with controls administered in a dose-
dependent  manner  with  increasing
doses  of  VEGF.  The  maximum
protection was provided at the 200 nM
dose (p=0.001). C: Treatment with the
glutathione  reductase  inhibitor
buthionine sulfoxime (BSO) increased
H2O2-mediated  reduction  in  cell
numbers by 22%. hVEGF165 at 200 ng/
ml  provided  the  greatest  protection,
increasing  cell  numbers  by  8%,
p<0.0005.  Cell  numbers  were
determined  using  a  Water  Soluble
Tetrazolium  (WST)-1  assay  and  are
expressed as percent of control. H2O2:
hydrogen peroxide.
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class III β-tubulin, which highlights the elongated neuronal
processes (Figure 1B, Antibody control and Figure 1C).
Oxidative stress: Twenty-four h H2O2 dose response studies
identified  800  μM  as  the  ideal  concentration,  reliably
producing a 40% reduction in cell numbers compared with
control  (Figure  2A).  This  dose  was  used  in  subsequent
experiments to test VEGF protection. 200 ng/ml of VEGF165
afforded the greatest protection to oxidative stress induced by
24 h exposure to 800 μM H2O2. There was a reduction in
percentage decrease of cell numbers when cells were co-
treated  with  VEGF  and  H2O2,  compared  with  controls
administered  in  a  dose-dependent  manner  with  increasing
doses of VEGF. The maximum protection was provided at the
200 nM dose (p=0.001; Figure 2B). BSO increased H2O2-
mediated reduction in cell numbers by 22%. hVEGF165 at
200 ng/mL provided the greatest protection, increasing cell
numbers by 8%, p<0.0005 (Figure 2C).
Bevacizumab was not cytotoxic at any of the doses tested
(p-values 0.34–0.69). This result was reflected in both WST-1
and CV assays (Figure 3A,B, respectively). H2O2 served as a
positive control and consistently reduced cell numbers by
50%, p<0.0005. hVEGF165 afforded a 12% increase in cell
numbers compared with control cells exposed to 800 μM
Figure 3. Effect of bevacizumab, following 24 h exposure, did not
reveal evidence of cytotoxicity at any of the doses tested. Hydrogen
peroxide (1 mM) served as a positive control. Cell numbers were
assessed using Water Soluble Tetrazolium (WST)-1 (A) and crystal
violet assays (B), and are expressed as percent of the control (*p-
value<0.001). Bev: Bevacizumab. Error bars are SEM n=8 for all
experiments.
H2O2,  p<0.005.  This  effect  was  completely  blocked  by
bevacizumab at 2.0 mg/ml, returning cell numbers to near
control levels (Figure 4).
DISCUSSION
Anti-VEGF  therapy  plays  a  significant  role  in  the
management of retinal and retinal vascular disorders [9–12].
Target therapy, though aimed against the angiogenic effect of
VEGF,  can  reduce  the  potential  benefit  of  VEGF  in
neuroprotection from oxidative stress. In our experiments, we
provide  evidence  to  suggest  that  addition  of  the  VEGF
inhibitor  bevacizumab,  while  not  toxic  to  differentiated
RGC-5 at clinically relevant doses, blocked the protective
effect of VEGF in our in vitro model.
In  the  human  eye,  there  is  increasing  evidence  that
pathogenic  oxidative  mechanisms  contribute  to  the
progression of pathological conditions such as age-related
macular degeneration and glaucoma [14–18]. Phagocytosis of
outer segments by the retinal pigment epithelium results in the
generation  of  reactive  oxygen  species  such  as  superoxide
anion, hydroxyl, and hydrogen peroxide [19]. In different cell
types, including vascular smooth muscles, VEGF expression
is triggered under the influence of oxidative stress. Castilla et
al. have demonstrated an increased VEGF expression in aortic
endothelial cells that were exposed to cytotoxic agents such
as hydrogen peroxide, cytochalasin, and cyclosporine [20]. In
this study, we used H2O2 to induce oxidative stress to replicate
the in vivo conditions that are implicated in the pathogenesis
of AMD.
The development of the transformed rat RGC-5 provided
a  constant  supply  of  cells  for  laboratory  investigation,
although their lack of morphologic characteristics of neurons
has raised debate [13]. A recent report describes the process
of differentiation of this cell line with the receptor tyrosine
kinase inhibitor Staurosporine. Treatment with Staurosporine
resulted  in  elongated  neuronal  processes  imitating  those
present in vivo, compared with the control RGC-5 [13]. Our
experiments further characterized this model, demonstrating
differential expression of class III β-tublin, which highlighted
the morphologic changes. This result thus provided an in vitro
model that better approximates retinal ganglion cells in vivo.
Several mechanisms have been elaborated to explain the
cytoprotective effect mediated by VEGF against oxidative
stress [21,22]. In a study evaluating the role of growth factor-
modulated antioxidant expression, Madhavan et al. [21] found
elevated expression of the antioxidant enzyme superoxide
dismutase 2 (SOD2). This enzyme protected neuronal cells
from oxidative stress when exposed to 3-NP, an inhibitor of
mitochondrial respiratory complex, in the presence of VEGF.
Similarly, in animal models of hyperoxic acute lung injury,
VEGF has been shown to protect vascular endothelial cells
through induction of heme oxygenase-1 (HO-1) [22]. In this
study, we demonstrated protection of differentiated retinal
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by  H2O2.  Experiments  using  the  glutathione  reductase
inhibitor BSO blunted this effect, indicating a potential role
of  glutathione  in  VEGF-mediated  cytoprotection.  An
alternative explanation is that the oxidative stress was more
robust in cells where endogenous reducing agents have been
depleted, and any minimal cytoprotective action of VEGF was
no longer evident.
Our conclusions are drawn from in vitro studies, which
are at best approximate and cannot mimic in vivo conditions.
Further, only one VEGF isoform was evaluated. Treatment
with  different  isoforms  may  have  highlighted  differences
between specific and non-specific VEGF inhibition. Lastly,
the increased presence of class III β-tubulin provides evidence
of  neuronal  elements,  but  this  is  not  specific  for  retinal
ganglion cells.
In  summary,  we  offer  in  vitro  evidence  that  VEGF
protection against oxidative stress is blocked by bevacizumab,
in a model of differentiated retinal ganglion cells.
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